Status:
COMPLETED
Cetuximab for Unresectable Cutaneous Squamous Cell Carcinoma - A National Retrospective Study
Lead Sponsor:
Centre Antoine Lacassagne
Conditions:
Squamous Cell Cutaneous Carcinoma of the Skin
Eligibility:
All Genders
18+ years
Brief Summary
Localized cutaneous squamous cell carcinoma (CSCC) is usually treated by radical surgery with or without radiotherapy. The cure rate is high around 90% of cases (1). Unresectable CSCC represents less ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Histologically Confirmed squamous cell cutaneous carcinoma of the skin (SCCS)
- Locally advanced SCCS that is surgically unresectable, or metastatic SCCS, with documented progression, and who received a treatment of Cetuximab in monotherapy,
- Patients have to be anti EGFR-naïve,
- Age ≥ 18 years
- Eastern Cooperative Oncology Group performance status ≤ 2; life expectancy ≥ 3 months
- Presence of at least one measurable target lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
- Adequate hematologic, hepatic, and renal functions
- Available medical data
- Chemotherapy naïve patient in metastatic or locally advanced conditions (Cisplatinum used concomitantly with radiotherapy is allowed)
- Exclusion criteria
- Prior radiotherapy within the last 4 weeks before the start of cetuximab (radiotherapy in concomitance with cetuximab is allowed if this is administrated in another lesion than the lesion treated by Cetuximab).
- Prior therapy with an agent that targets EGFR
- Instable systemic diseases or active uncontrolled infections.
Exclusion
Key Trial Info
Start Date :
June 30 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 11 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03325738
Start Date
June 30 2017
End Date
September 11 2018
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PEYRADE Frédéric
Nice, France, 06189